PPARalpha activators inhibit cytokine-induced vascular cell adhesion molecule-1 expression in human endothelial cells. - Wikidata - awgldk - TriplyDB

PPARalpha activators inhibit cytokine-induced vascular cell adhesion molecule-1 expression in human endothelial cells.

PPARalpha activators inhibit cytokine-induced vascular cell adhesion molecule-1 expression in human endothelial cells.

http://www.wikidata.org/entity/Q42267879

about

MicroRNA-21 targets peroxisome proliferators-activated receptor-alpha in an autoregulatory loop to modulate flow-induced endothelial inflammation SUMOylation of human peroxisome proliferator-activated receptor alpha inhibits its trans-activity through the recruitment of the nuclear corepressor NCoR Sorting out the roles of PPAR alpha in energy metabolism and vascular homeostasis PPARs and the cardiovascular system Troglitazone, a PPAR-gamma activator prevents endothelial cell adhesion molecule expression and lymphocyte adhesion mediated by TNF-alpha Emerging role of mast cells and macrophages in cardiovascular and metabolic diseases Role of lipotoxicity in endothelial dysfunction MicroRNAs in flow-dependent vascular remodelling Endothelial dysfunction: a comprehensive appraisal.Vascular endothelium as a target of beraprost sodium and fenofibrate for antiatherosclerotic therapy in type 2 diabetes mellitus Fenofibrate: a novel formulation (Triglide) in the treatment of lipid disorders: a review Fenofibric acid: a new fibrate approved for use in combination with statin for the treatment of mixed dyslipidemia Gng12 is a novel negative regulator of LPS-induced inflammation in the microglial cell line BV-2 Primary prevention of diabetic retinopathy with fibrates: a retrospective, matched cohort study Targeting vascular NADPH oxidase 1 blocks tumor angiogenesis through a PPARα mediated mechanism Atherosclerosis pathophysiology and the role of novel risk factors: a clinicobiochemical perspective.Triglycerides and HDL cholesterol: stars or second leads in diabetes?Is spaceflight-induced immune dysfunction linked to systemic changes in metabolism?Peroxisome proliferator-activated receptors in the cardiovascular system.Homocysteine and Hypertension in Diabetes: Does PPARgamma Have a Regulatory Role?VLDL hydrolysis by hepatic lipase regulates PPARδ transcriptional responses PPAR agonists as direct modulators of the vessel wall in cardiovascular disease.L-carnitine protects against carboplatin-mediated renal injury: AMPK- and PPARα-dependent inactivation of NFAT3.Re-emergence of fibrates in the management of dyslipidemia and cardiovascular risk.Peroxisome proliferator-activated receptors in vascular biology and atherosclerosis: emerging insights for evolving paradigms.Peroxisome Proliferator-Activated Receptors Protect against Apoptosis via 14-3-3.Anti-tumor mechanisms of valproate: a novel role for an old drug.Peroxisome proliferator-activated receptors in atherosclerosis and inflammation--an update.Anti-inflammatory effect of docosahexaenoic acid on cytokine-induced adhesion molecule expression in human retinal vascular endothelial cells Modification in oxidative stress, inflammation, and lipoprotein assembly in response to hepatocyte nuclear factor 4alpha knockdown in intestinal epithelial cells.Peroxisome proliferator-activated receptors.Specific monocyte adhesion to endothelial cells induced by oxidized phospholipids involves activation of cPLA2 and lipoxygenase.Peroxisome proliferator-activated receptor gamma and atherosclerosis.Dual roles for lipolysis and oxidation in peroxisome proliferation-activator receptor responses to electronegative low density lipoprotein Peroxisome proliferator-activated receptor-gamma activators inhibit IFN-gamma-induced expression of the T cell-active CXC chemokines IP-10, Mig, and I-TAC in human endothelial cells.PPAR activators as antiinflammatory mediators in human T lymphocytes: implications for atherosclerosis and transplantation-associated arteriosclerosis.High-density lipoprotein hydrolysis by endothelial lipase activates PPARalpha: a candidate mechanism for high-density lipoprotein-mediated repression of leukocyte adhesion.Vascular inflammation as a therapeutic target for prevention of cardiovascular disease.Orphan nuclear receptors find a home in the arterial wall.Atherosclerosis in type 2 diabetes: a role for fibrate therapy?

P2860

Q24305294-D0DDD8FE-EA41-4FFE-B21E-5E69DA30EDAA Q24324236-E46EECC9-168A-484C-9E93-38B0F1B1EF4A Q24541529-1E9EB9EE-BAAE-41F0-863C-1639620E6428 Q24642728-194D920B-C627-48E7-ACEC-ED7F128A79FE Q24793384-2E122442-D809-4C5E-B983-0DD231B8C7FD Q26825467-05878587-EE63-43FD-812D-FF12D7FD347C Q27000731-EF867E85-4AA6-4AAF-A61F-14089F5802E5 Q27002530-61B830CE-65F1-46D4-9DFD-8AC2D8B9CADE Q28195411-49E12BEB-F471-4D8E-8358-03C9F4713A44 Q28219328-C245A7FD-CC95-4576-A040-91F78FBE4480 Q28220294-CF783A16-FC70-47C1-878D-A8820241D218 Q28284661-36420E80-4605-4FBE-A00B-76BCB108ABBC Q28576862-636375C8-E2E6-4A30-9A9A-13315E4DCB88 Q28661253-984288E8-970C-44F5-9F79-C058B27DAAB5 Q28743072-51A50117-0858-417E-AE84-4F4E2C171B55 Q33306319-DE6AD611-8762-46AD-8A29-EF7DABDED56E Q33610637-9A3DD031-2823-4933-81A5-2D9C11253B50 Q33724786-3E6C8A0B-03D1-4959-B148-2C9779D7751A Q33850995-3DF4C8B2-393E-4AE7-80EA-4CCBA7B3D92F Q33953983-BD2A577D-0AC6-4E80-BE73-4F3B9F1B0597 Q33959265-4E61D4A4-D15E-43A6-B0F0-2F41DA3C755E Q33996831-4F1FD34D-B037-4AFD-AE14-555FC61FA7CD Q34000195-0F7F9454-98C5-47C7-A40D-A87DA8AA2877 Q34107307-7F3C74B3-684C-4B7F-81B5-42B38E9D16E4 Q34107495-46C6D6C3-CE3D-431B-8085-88B9C0ADFB41 Q34123741-DBAFB808-EF48-4496-B786-88E260DAF732 Q34147644-E5684938-5078-43D3-A6B3-BF9F512A9AD0 Q34290988-8E7A188D-413B-40FE-88C7-CBC479589CC9 Q34390960-EFF4B2D8-836D-48CC-A92E-6663B03A92DD Q34412525-7F638469-EBBE-4E9B-BC05-8ACE47E407FE Q34482158-8701658B-4B22-4508-B5DE-3BB5AD819F12 Q34492025-180B0A5E-6189-461F-A4A3-9D57F9E724FE Q34492831-AB2443C3-3036-4971-A243-74A575268B00 Q34509915-08CAF43B-F656-4C29-85AA-74FD9E12F57D Q34509942-6908A840-3018-41E6-8690-A40E418C4239 Q34509964-323FA73B-5D8F-423A-8175-B42BC226C9DF Q34510249-D7F08F24-11F3-408A-B6E8-753D5FA41969 Q34514026-73E8F2A4-05C2-4FBA-B799-61050A5591A2 Q34586834-9083B94C-AF76-456F-8BA0-B36DAC2384D0 Q34730108-F6E23A79-8445-459B-A9F8-D6625C2650CF

P2860

PPARalpha activators inhibit cytokine-induced vascular cell adhesion molecule-1 expression in human endothelial cells.

http://www.wikidata.org/entity/Q42267879

description

1999 nî lūn-bûn

@nan

1999年の論文

@ja

1999年論文

@yue

1999年論文

@zh-hant

1999年論文

@zh-hk

1999年論文

@zh-mo

1999年論文

@zh-tw

1999年论文

@wuu

1999年论文

@zh

1999年论文

@zh-cn

name

PPARalpha activators inhibit c ...... on in human endothelial cells.

@en

PPARalpha activators inhibit c ...... on in human endothelial cells.

@nl

type

label

PPARalpha activators inhibit c ...... on in human endothelial cells.

@en

PPARalpha activators inhibit c ...... on in human endothelial cells.

@nl

prefLabel

PPARalpha activators inhibit c ...... on in human endothelial cells.

@en

PPARalpha activators inhibit c ...... on in human endothelial cells.

@nl

P1433

Q42267879-84314BA9-E390-4E26-9CFF-A23CFF667D44

P1476

Q42267879-BA3BC163-5145-4DEA-ACCE-A2D57B4F6D90

P2093

Q42267879-530ACBB5-A1DF-4079-BC78-FFD83D59008D

Q42267879-6CCB40C0-635E-48DF-AEC1-B6B7907A9232

Q42267879-790597C0-6E25-487D-8AF1-2871F5593AC8

Q42267879-DAF93AAB-4588-431F-AC02-4D27B18B5FE3

Q42267879-EEB716FE-2DF5-40CB-B2D9-474AF51E2DD9

P2860

Q42267879-0900BAE1-CAF6-4E9E-8AA0-22E334198BB4

Q42267879-0AC3D977-9381-4BE3-BB82-54FE86BB6B0D

Q42267879-13B69319-0B0C-4D38-B558-580D6122FBC2

Q42267879-3202EF41-92EC-4E56-907F-B0A7B2593B8B

Q42267879-383643F7-F243-4591-B0E9-386C68132763

Q42267879-39417705-E903-4CA9-A24A-86F819F64F3C

Q42267879-54F8BB79-1851-4D27-8FE3-DB7E32BE81FF

Q42267879-6F8BE8AB-41C0-4E45-90D1-0881FAB21C88

Q42267879-84D457D0-43FE-4476-9372-E0C5B7C2798A

Q42267879-9103C038-3E2C-42FD-84B2-92AC60F4A18C

P304

Q42267879-BE7E8E5F-94C5-4B2A-BF27-FCF0074982D2

P31

Q42267879-B4063E8F-2079-47AF-954F-3D16DF660D50

P356

Q42267879-F3589525-DFF1-44D4-8073-46BEF0FA907E

P407

Q42267879-8384672E-C43F-40CE-A599-92902969EE6B

P433

Q42267879-082CFEB1-1E95-4F06-983E-7607D2B2A765

P478

Q42267879-B5387C08-499E-46D4-84E8-A6FC7CA40F88

P577

Q42267879-C3620768-B6FD-48FF-A52F-D2E7D5024089

P698

Q42267879-0CBE4A70-FFDA-4135-9919-76530948D02B

P921

Q42267879-D6D60C97-43E0-46E3-9497-8F53358C0EFE

P932

Q42267879-EA31968D-FB3F-4DD8-89C2-E470E9677ABF

P356

01.CIR.99.24.3125

P1433

P1476

PPARalpha activators inhibit c ...... on in human endothelial cells.

@en

P2093

G K Sukhova

http://www.w3.org/2001/XMLSchema#string

J Plutzky

http://www.w3.org/2001/XMLSchema#string

N Marx

http://www.w3.org/2001/XMLSchema#string

P Libby

http://www.w3.org/2001/XMLSchema#string

T Collins

http://www.w3.org/2001/XMLSchema#string

P2860

Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferator-activated receptors alpha and gamma

CREB-binding protein/p300 are transcriptional coactivators of p65

Targeted disruption of the alpha isoform of the peroxisome proliferator-activated receptor gene in mice results in abolishment of the pleiotropic effects of peroxisome proliferators

High-efficiency transformation of mammalian cells by plasmid DNA

p300 functions as a coactivator for the peroxisome proliferator-activated receptor alpha

Expression of peroxisome proliferator-activated receptor alpha (PPAR alpha) in primary cultures of human vascular endothelial cells

Mechanism of action of fibrates on lipid and lipoprotein metabolism

Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors alpha and delta

Traffic signals for lymphocyte recirculation and leukocyte emigration: the multistep paradigm

Vascular cell adhesion molecule-1 is expressed in human coronary atherosclerotic plaques. Implications for the mode of progression of advanced coronary atherosclerosis.

P304

3125-3131

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1161/01.CIR.99.24.3125

http://www.w3.org/2001/XMLSchema#string

P407

P433

24

http://www.w3.org/2001/XMLSchema#string

P478

99

http://www.w3.org/2001/XMLSchema#string

P577

1999-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

10377075

http://www.w3.org/2001/XMLSchema#string

P921

P932

4231776

http://www.w3.org/2001/XMLSchema#string